AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Karolinska Development

Report Publication Announcement Feb 21, 2012

3168_rns_2012-02-21_f4bc57a2-caf3-48f3-ac07-bea6c0a7a178.pdf

Report Publication Announcement

Open in Viewer

Opens in native device viewer

Karolinska Development – Year‐End Report, conference call Wednesday, February 22

STOCKHOLM ‐ February 21, 2012. Karolinska Development will publish its Year‐End Report for 2011 at 08.30 CET on Wednesday, February 22. The company will also host a conference call on the same day at 14.00 CET.

Participant access numbers: +46 (0) 8 50 55 97 72, UK: +44 (0) 20 77 50 99 50

Hosts: Torbjörn Bjerke, CEO, and Gunnar Casserstedt, CFO.

For further information, please contact:

Benjamin Nordin, IRO, Karolinska Development AB Phone: +46 (0)73 093 60 80, e‐mail: [email protected]

TO THE EDITORS

About Karolinska Development AB

Karolinska Development aims to create value for investors, patients, and researchers by developing innovations from world class science into products that can be sold or out‐licensed with high returns. The business model is to: SELECT the most commercially attractive medical innovations; DEVELOP innovations to the stage where the greatest return on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out‐licensing of products. An exclusive deal flow agreement with Karolinska Institutet Innovations AB, along with other cooperation agreements with leading Nordic universities, delivers a continuous flow of innovations. Today, the portfolio consists of 36 projects, of which 14 are in clinical development. For more information, please visit www.karolinskadevelopment.com.

Karolinska Development is listed on NASDAQ OMX. Karolinska Development may be required to disclose the information provided herein pursuant to the Securities Markets Act.

Talk to a Data Expert

Have a question? We'll get back to you promptly.